This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdeliverysystems and medical devices.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. The Charleston Regional Development Alliance (CRDA) is supporting SHL Medical by facilitating valuable connections to best-in-class service providers in the area.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Our Social Media Platform.
Conjugation with a Variety of Molecular Conjugates and Labels The combination of the conjugates / labels with molecules ( proteins, peptides, antibodies and small molecules ) is being used abundantly for several applications, ranging from therapeutics and diagnostics to isolation and characterization of drugdeliverysystems.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. million adults in the United States.
With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.
Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drugdevelopers. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
With that in mind, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry. Tieming Ruan, Senior Director of Device Development, Alexion Pharmaceuticals.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Lipid nanoparticle drugdelivery was in the spotlight during the Covid-19 pandemic.
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content